Oral eliglustat transmucosal delivery system
The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules. In addition, unlike the dosing prerequisite for commercially available eliglustat capsules, the oral eliglustat transmucosal dosage form described herein can be administered to patients with Gaucher disease type 1 without pre-determination of patients' CYP2D6 genotype.
1. An oral transmucosal dosage form comprising a non-disintegrating solid mass comprising:
a. a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater,
b. a buffering agent, and
c. not more than 70 mg eliglustat,
wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec shear rate.
2. The oral transmucosal delivery system of claim 1 , wherein the eliglustat is 5 mg to 20 mg.
3. The oral transmucosal dosage form of claim 1 , wherein the eliglustat is eliglustat is eliglustat tartrate or eliglustat hemitartrate.
4. The oral transmucosal dosage form of claim 1 , wherein the buffering agent is a phosphate buffer, citrate buffer, organic buffer, mineral buffer, or combinations thereof.
5. The oral transmucosal dosage form of claim 1 , wherein the buffering agent is disodium hydrogen phosphate.
6. The oral transmucosal dosage form of claim 1 , wherein the hydrophilic viscosity modifying agent is selected from:
a. a natural gum selected from the group consisting of acacia, tragacanth, xanthan gum, alginates, agar, carrageenan, karaya gum, guar gum, locust bean gum, modified starch, gelatin and combinations thereof;
b. synthetic gum selected from the group consisting of a carbomer, polycarbophil, povidone (polyvinylpyrrolidone), polydextrose, polyethylene oxide (PEO), cellulose derivative, and combinations thereof; or
c. combinations thereof.
7. The oral transmucosal dosage form of claim 6 , wherein the cellulose derivative is selected from the group consisting of hydroxypropyl methyl cellulose, methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethylcellulose sodium, and combinations thereof.
8. The oral transmucosal dosage form of claim 1 , comprising at least two hydrophilic viscosity modifying agents.
9. The oral transmucosal dosage form of claim 1 , further comprising a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons.
10. The oral transmucosal dosage form of claim 9 , wherein at least about 50% (wt/wt) of the non-disintegrating solid mass consists of the hydrophilic viscosity modifying agent, buffering agent and the low molecular weight water soluble component.
11. The oral transmucosal dosage form of claim 9 , wherein the low molecular weight water soluble component is selected from the group consisting of monosaccharides, disaccharides, polyols, and combinations thereof.
12. The oral transmucosal dosage form of claim 11 , wherein the polyol is selected from the group consisting of sorbitol, mannitol, maltitol, erythritol, hydrogenated starch hydrolysates, xylitol, isomalt, lactitol, and combinations thereof.
13. The oral transmucosal dosage form of claim 1 , wherein the dosage form is about 200 mg to about 300 mg.
14. The oral transmucosal dosage form of claim 1 , wherein the oral transmucosal dosage form provides an oral cavity residence time of about 10 minutes to about 20 minutes.
15. The oral transmucosal dosage form of claim 1 , wherein more than 50% of eliglustat is released from the dosage form within 20 minutes in simulated saliva fluid.
16. The oral transmucosal dosage form of claim 1 , wherein the dosage form is a tablet, a lollipop, or a film.
17. A method of making an oral transmucosal dosage form comprising:
a. mixing (i) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (ii) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons, (iii) a buffering agent and (iv) eliglustat to form a mixture; and
b. compacting the mixture into a tablet or a lollipop;
wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec shear rate.
18. The method of claim 17 , further comprising moist heating the compacted mixture to form a pliable dosage form.
19. A method of making an oral transmucosal dosage form comprising:
a. solubilizing and/or dispersing eliglustat in a mixture of (i) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (ii) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons, and (iii) a buffering agent; and
b. casting the mixture into films, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes;
wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec shear rate.
20. A method of treating a subject with Gaucher disease type 1 , the method comprising administering the dosage form of claim 1 , wherein the dosage form is administered to the subject without pre-determining the subject's CYP2D6 genotype.